Antibiotic resistance is a major world-wide health problem that is threatening our ability to treat common infectious diseases. CDRD is collaborating with UK partners LifeArc and the Defence Science and Technology Laboratory (Dstl), to ID antibacterial drug targets in the fight against antibiotic resistance.
Sitka Biopharma Inc., a spin-off of CDRD & the University of British Columbia (UBC) has partnered with a major UK cancer centre to advance Sitka’s bladder cancer treatment into an early phase clinical trial.
CDRD & Aequus are collaborating & sharing respective expertise that could lead to new cannabinoid therapeutics and a pathway to clinical trials, particularly in neurological movement disorders.
Novelogics Biotechnology, Inc. & CDRD are collaborating to further characterize Novelogics’ internally-developed antibody immunotherapy for treating cancer.
Dr. Philippe Séguéla from the Montreal Neurological Institute has been selected to work with CDRD to further develop his progressive MS translational project focused on blocking specific ion channels in the brain.
Meet Amber, Katrina from Pigeon Lake, AB, Lucas from Rorketon, MB and Destiny from Gift Lake, AB who have joined the CDRD team in our Target Validation and Analytical Chemistry divisions from May 15-19.
CDRD is a partner in one of 16 new collaborative research projects announced by BioCanRx. These projects are aimed at finding improved treatment options and outcomes for cancer patients and developing clinical Chimeric Antigen Receptor modified T cell (CAR-T) manufacturing capabilities in Canada.
Health sciences researchers, entrepreneurs, and companies alike have the opportunity to collaborate with CDRD and thereby access its full suite of expertise, infrastructure, and broad partnerships and networks.
CDRD BY THE NUMBERS:
Headquartered in Vancouver, British Columbia, The Centre for Drug Research and Development (CDRD) is Canada’s national drug development and commercialization engine.
We work in partnership with academia, industry, government and foundations, to provide the specialized expertise and infrastructure to identify and de-risk promising discoveries generated by health-related research, and transform them into commercially viable investment opportunities for the private sector – and ultimately into innovative new therapies for patients.
In doing so, CDRD is actively growing our national health sciences industry into a wholly-optimized generator of economic prosperity for the country.
Since 2008, Canada’s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR).